Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial.

Christian SchoergenhoferEva-Luise HoblMichael SchwameisGeorg GelbeneggerThomas StaudingerGottfried HeinzWalter S SpeidlChristian ZaunerBirgit ReiterIrene LangBernd Jilma

Published in: European journal of clinical investigation (2017)

There is a very high prevalence of HTPR in critically ill patients on peroral ASA therapy, caused by an incomplete suppression of TXB2 and/or by impaired absorption of ASA.

Keyphrases

stem cells
mesenchymal stem cells